EVEREST MED (01952) surged more than 5%, with shares up 4.07% to HK$48.56 at the time of writing, recording a turnover of HK$158 million. The company announced on its official WeChat account that NEFECON® (budesonide enteric-coated capsules) presented multiple new research findings on IgA nephropathy patients at the 58th American Society of Nephrology Kidney Week (ASN Kidney Week 2025).
As evidence continues to accumulate for NEFECON® in the Chinese population, these results further validate its significant clinical value in the new management strategy of "targeted treatment, early intervention, and long-term therapy" for IgA nephropathy. The efficacy of NEFECON® in specific patient groups has also been confirmed, reinforcing its foundational role as a first-line treatment for IgA nephropathy.
The studies presented at ASN incorporated multiple real-world evidence (RWE) from China, systematically demonstrating NEFECON®'s unique mechanism of targeting gut mucosal immunity to intervene in disease progression at its source. This provides critical evidence-based support for standardized treatment throughout the course of IgA nephropathy.
Over 70% of Chinese IgA nephropathy patients already exhibit disease progression at diagnosis, highlighting delayed treatment initiation. Currently, China has approximately 5 million IgA nephropathy patients, with over 120,000 new cases diagnosed annually, representing a significant unmet clinical need. Therefore, early and long-term targeted treatment to slow disease progression and preserve kidney function is crucial in managing IgA nephropathy.
Comments